The table on page 37 of the application as filed shows that the compounds of examples 1, 4 and 6 do indeed inhibit the JNK3 receptor.Taking into account the now limited scope of the claims, it is plausible that essentially all the compounds claimed show this effect and are thus suitable for the treatment of diseases involving the JNK pathway, such as auto-immune and inflammatory diseases and cance